kidney cancer

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Fierce Pharma
Pfizer
Sutent
kidney cancer
Flag link:
Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
Flag link:
Opdivo combo shows early survival benefit in kidney cancer
Opdivo combo shows early survival benefit in kidney cancer
BioPharma Dive
Opdivo
Yervoy
Bristol-Myers Squibb
kidney cancer
Flag link:
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy
Bristol-Myers Squibb
kidney cancer
Opdivo
Yervoy
Flag link:
Aveo soars as long-beleaguered cancer drug nears approval
Aveo soars as long-beleaguered cancer drug nears approval
Fierce Biotech
Aveo
Europe
tivozanib
kidney cancer
Flag link:
Ac­celeron dumps dalantercept after kidney cancer trial fail
Ac­celeron dumps dalantercept after kidney cancer trial fail
Fierce Biotech
Acceleron
dalantercept
kidney cancer
clinical trials
Flag link:
Roche says Phase II trial supports twin treatment for kidney cancer
Roche says Phase II trial supports twin treatment for kidney cancer
Yahoo/Reuters
Roche
kidney cancer
Tecentriq
Flag link:
What's Pfizer's Excuse for Not Buying Exelixis?
What's Pfizer's Excuse for Not Buying Exelixis?
Motley Fool
Pfizer
Exelixis
M&A
Cabometyx
kidney cancer
Sutent
Flag link:
Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Motley Fool
Pfizer
Bristol-Myers Squibb
Exelixis
Cabometyx
kidney cancer
Sutent
Opdivo
Flag link:
Exelixis and Pfizer drugs compete in kidney cancer trial
Exelixis and Pfizer drugs compete in kidney cancer trial
Yahoo/Reuters
kidney cancer
Exelixis
Pfizer
Sutent
Cabometyx
Flag link:
Pfizer's Sutent comes up big in adjuvant trial, staving off cancer for 6 years-plus
Pfizer's Sutent comes up big in adjuvant trial, staving off cancer for 6 years-plus
Fierce Pharma
Pfizer
Sutent
kidney cancer
Flag link:
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Motley Fool
Pfizer
Sutent
kidney cancer
Exelixis
Bristol-Myers Squibb
Novartis
Flag link:
UK cost agency rejects Bristol's Opdivo for kidney cancer
UK cost agency rejects Bristol's Opdivo for kidney cancer
Yahoo/Reuters
UK
Bristol-Myers Squibb
Opdivo
kidney cancer
NICE
Flag link:
Eisai's kidney drug wins expanded indication in the U.S.
Eisai's kidney drug wins expanded indication in the U.S.
BioPharma Dive
Eisai
advanced renal cell carcinoma
kidney cancer
Lenvima
RCC
Flag link:
Aveo to pay $4m to settle investor fraud charges
Aveo to pay $4m to settle investor fraud charges
Stat
Aveo Pharmaceuticals
tivozanib
kidney cancer
investors
Flag link:
​Aveo’s kidney cancer drug submitted for approval in Europe
​Aveo’s kidney cancer drug submitted for approval in Europe
Bizjournals.com
Aveo Oncology
kidney cancer
tivozanib
Flag link:
Eisai scores FDA priority review for bigger Lenvima use in kidney cancer
Eisai scores FDA priority review for bigger Lenvima use in kidney cancer
Fierce Pharma
Eisai
Lenvima
kidney cancer
FDA
priority review
Flag link:
Bristol-Myers nabs FDA priority review for new Opdivo use in kidney cancer
Bristol-Myers nabs FDA priority review for new Opdivo use in kidney cancer
Fierce Pharma
Bristol-Myers Squibb
FDA
priority review
Opdivo
kidney cancer
Flag link:
Kidney Cancer Drug Boxing Match
Kidney Cancer Drug Boxing Match
Motley Fool
kidney cancer
Bristol-Myers Squibb
Novartis
Exelixis
Opdivo
Cometriq
Afinitor
Flag link: